<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="f158fe10-d5dc-4432-b2c9-fc665401291b"><labelDrug name="Revatio"><Normalization><mmtx cui="C1614029" preferredWord="Revatio" semType="phsu, orch"/></Normalization></labelDrug><generic name="sildenafil citrate"/><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1" text="Drug Label for drug brand Revatio, containing sildenafil citrate." type="negative"><entity charOffset="46:64" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.0" text="sildenafil citrate" type="Biomedical_Entity"><Normalization><mmtx cui="C0724693" phraseText="sildenafil citrate." preferredWord="Sildenafil citrate" semType="phsu, orch"/><RxNorm RxCui="136411"/></Normalization></entity><entity charOffset="0:19" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.1" text="drug drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0013231" phraseText="Drug Label for drug brand Revatio," preferredWord="Drugs, Non-Prescription" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="26:33" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.2" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="Drug Label for drug brand Revatio," preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.0"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.0"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.2"/></sentence><sentence biomedicalEntities="1" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3" lineNumber="7" text="&lt;main&gt;REVATIO is contraindicated in patients with:" type="regular"><entity charOffset="6:13" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3.e.0" text="REVATIO" type="Drug"><Normalization><mmtx cui="C1614029" phraseText="&gt;REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="17:32" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3.e.1" text="contraindicated" type="Caution_Interaction"/><entity charOffset="17:32" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3.e.3" text="contraindicated" type="SPAN"/><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3.e.1"><relations><relation type="hasSeverity"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.4.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3.e.0"/></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="1" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.4" lineNumber="9" text="&lt;item&gt;Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension see Warnings and Precautions (5.2)." type="irregular"><entity charOffset="122:133" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.4.e.0" text="hypotension" type="Specific_Interaction"/><entity charOffset="25:41" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.4.e.2" text="organic nitrates" type="Drug_Class"><Normalization><RxNorm RxCui="1427579"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.4.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.4.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.4.e.2"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3" text="&lt;main&gt;REVATIO is contraindicated in patients with:"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.3.e.0"/></ellipsisSentence></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.4.e.2"/></sentence><sentence biomedicalEntities="1" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.7" lineNumber="16" text="&lt;item&gt;Use with organic nitrates (4)" type="irregular"><entity charOffset="15:31" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.7.e.0" text="organic nitrates" type="Drug_Class"><Normalization><RxNorm RxCui="1427579"/></Normalization></entity><entity charOffset="6:9" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.7.e.1" text="Use" type="Caution_Interaction"/><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.7.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.7.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.7.e.0"/></relation><relation type="hasObject"><labelDrug text="Revatio"/><normalization><mmtx><preferredWord>Revatio</preferredWord><phraseText>&gt;REVATIO</phraseText><cuiCode>C1614029</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.7.e.0"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27" text="Before prescribing REVATIO, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension BP less than 90/50, fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction). " type="negative"><entity charOffset="175:191" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27.e.0" text="antihypertensive" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="patients on antihypertensive therapy" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="19:26" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27.e.1" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="prescribing REVATIO," preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28" lineNumber="47" text="Monitor blood pressure when co-administering blood pressure lowering drugs with REVATIO." type="regular"><entity charOffset="45:74" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.0" text="blood pressure lowering drugs" type="Drug_Class"><Normalization><mmtx cui="C0003364" phraseText="blood pressure lowering drugs with REVATIO." preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="1629"/></Normalization></entity><entity charOffset="80:87" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.1" text="REVATIO" type="Drug"><Normalization><mmtx cui="C1614029" phraseText="blood pressure lowering drugs with REVATIO." preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="0:7" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.2" text="Monitor" type="Caution_Interaction"/><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.0" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.1" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.2" type="Caution_Interaction"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31" text="Since there are no clinical data on administration of REVATIO to patients with veno-occlusive disease, administration of REVATIO to such patients is not recommended. " type="negative"><entity charOffset="121:128" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.0" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="administration of REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="54:61" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.1" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="no clinical data on administration of REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="16:32" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.2" text="no data" type="Biomedical_Entity"><Normalization><mmtx cui="C1572381" phraseText="no clinical data on administration of REVATIO" preferredWord="No Data re: Ingredient" semType="phsu"/><RxNorm RxCui="53704"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.0"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36" lineNumber="55" text="The incidence of epistaxis was also higher in REVATIO-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist)." type="regular"><entity charOffset="46:53" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.0" text="REVATIO" type="Drug"><Normalization><mmtx cui="C1614029" phraseText="also higher in REVATIO-treated patients" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="78:115" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.1" text="concomitant oral vitamin K antagonist" type="Drug_Class"><Normalization><mmtx cui="C2267235" phraseText="with a concomitant oral vitamin K antagonist" preferredWord="Vitamin K Antagonist [EPC]" semType="phsu"/><RxNorm RxCui="984607"/></Normalization></entity><entity charOffset="17:26" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.2" text="epistaxis" type="Specific_Interaction"/><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.0" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.1" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.2" type="Specific_Interaction"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39" text="When used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including sildenafil. " type="negative"><entity charOffset="235:278" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39.e.0" text="phosphodiesterase type 5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="of phosphodiesterase type 5 (PDE-5) inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="8228"/></Normalization></entity><entity charOffset="290:300" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39.e.1" text="sildenafil" type="Biomedical_Entity"><Normalization><mmtx cui="C0529793" phraseText="sildenafil." preferredWord="sildenafil" semType="phsu, orch"/><RxNorm RxCui="136411"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39.e.0" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39.e.1"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42" text="Advise patients to seek immediate medical attention in the event of a sudden loss of vision in one or both eyes while taking PDE-5 inhibitors, including REVATIO. " type="negative"><entity charOffset="153:160" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42.e.0" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="REVATIO." preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="125:141" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42.e.1" text="pde-5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="taking PDE-5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="1022271"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42.e.0"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43" text="Physicians should also discuss the increased risk of NAION with patients who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such as PDE-5 inhibitors." type="negative"><entity charOffset="215:231" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43.e.0" text="pde-5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="such as PDE-5 inhibitors." preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="1022271"/></Normalization></entity><entity charOffset="193:205" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43.e.1" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="affected by use of vasodilators," preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43.e.0"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44" text="There are no controlled clinical data on the safety or efficacy of REVATIO in patients with retinitis pigmentosa, a minority whom have genetic disorders of retinal phosphodiesterases. " type="negative"><entity charOffset="67:74" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44.e.0" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="efficacy of REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="10:37" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44.e.1" text="no data" type="Biomedical_Entity"><Normalization><mmtx cui="C1572381" phraseText="no controlled clinical data on the safety" preferredWord="No Data re: Ingredient" semType="phsu"/><RxNorm RxCui="53704"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44.e.0"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47" text="Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in temporal association with the use of PDE-5 inhibitors, including REVATIO. " type="negative"><entity charOffset="184:191" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47.e.0" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="REVATIO." preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="156:172" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47.e.1" text="pde-5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="of PDE-5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="1022271"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47.e.0"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51" text="Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE-5 inhibitors, including REVATIO." type="negative"><entity charOffset="141:148" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51.e.0" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="REVATIO." preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="113:129" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51.e.1" text="pde-5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="taking PDE-5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="1022271"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51.e.0"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53" text="Sildenafil is also marketed as VIAGRA. " type="negative"><entity charOffset="31:37" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53.e.0" text="viagra" type="Biomedical_Entity"><Normalization><mmtx cui="C0663448" phraseText="marketed as VIAGRA." preferredWord="Viagra" semType="phsu, orch"/><RxNorm RxCui="190465"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53.e.1" text="sildenafil" type="Biomedical_Entity"><Normalization><mmtx cui="C0529793" phraseText="Sildenafil" preferredWord="sildenafil" semType="phsu, orch"/><RxNorm RxCui="136411"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53.e.0"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54" text="The safety and efficacy of combinations of REVATIO with VIAGRA or other PDE-5 inhibitors have not been studied. " type="negative"><entity charOffset="56:62" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.0" text="viagra" type="Biomedical_Entity"><Normalization><mmtx cui="C0663448" phraseText="with VIAGRA" preferredWord="Viagra" semType="phsu, orch"/><RxNorm RxCui="190465"/></Normalization></entity><entity charOffset="72:88" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.1" text="pde-5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="other PDE-5 inhibitors" preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="1022271"/></Normalization></entity><entity charOffset="43:50" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.2" text="revatio" type="Biomedical_Entity"><Normalization><mmtx cui="C1614029" phraseText="efficacy of combinations of REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.0" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.1"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.0"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55" lineNumber="71" text="Inform patients taking REVATIO not to take VIAGRA or other PDE-5 inhibitors." type="regular"><entity charOffset="31:42" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.0" text="not to take" type="Caution_Interaction"/><entity charOffset="23:30" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.2" text="REVATIO" type="Drug"><Normalization><mmtx cui="C1614029" phraseText="REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="43:49" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.3" text="VIAGRA" type="Drug"><Normalization><mmtx cui="C0663448" phraseText="VIAGRA" preferredWord="Viagra" semType="phsu, orch"/><RxNorm RxCui="190465"/></Normalization></entity><entity charOffset="59:75" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.4" text="PDE-5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="other PDE-5 inhibitors." preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="1022271"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.4" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.3" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.3" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.4"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64" lineNumber="86" text="&lt;item&gt;Concomitant alpha-blockers or amlodipine: Note additive blood pressure lowering effects. " type="irregular"><entity charOffset="53:93" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.0" text="additive blood pressure lowering effects" type="Specific_Interaction"/><entity charOffset="18:32" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.2" text="alpha-blockers" type="Drug_Class"><Normalization><mmtx cui="C0001641" phraseText="&gt;Concomitant alpha-blockers" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/><RxNorm RxCui="1023426"/></Normalization></entity><entity charOffset="36:46" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.3" text="amlodipine" type="Drug"><Normalization><mmtx cui="C0051696" phraseText="amlodipine" preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.2"/></relation><relation type="hasObject"><labelDrug text="Revatio"/><normalization><mmtx><preferredWord>Revatio</preferredWord><phraseText>&gt;REVATIO</phraseText><cuiCode>C1614029</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.2"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66" lineNumber="88" text="&lt;item&gt;Use with ritonavir and other potent CYP3A inhibitors: Not recommended. " type="irregular"><entity charOffset="60:75" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.0" text="Not recommended" type="Caution_Interaction"/><entity charOffset="15:24" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.2" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="&gt;Use with ritonavir" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="35:58" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.3" text="potent CYP3A inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.2"/></relation><relation type="hasObject"><labelDrug text="Revatio"/><normalization><mmtx><preferredWord>Revatio</preferredWord><phraseText>&gt;REVATIO</phraseText><cuiCode>C1614029</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.2"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68" lineNumber="90" text="&lt;item&gt;Concomitant PDE-5 inhibitors: Avoid use with Viagra or other PDE-5 inhibitors. " type="irregular"><entity charOffset="36:41" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.0" text="Avoid" type="Caution_Interaction"/><entity charOffset="51:57" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.2" text="Viagra" type="Drug"><Normalization><mmtx cui="C0663448" phraseText="use with Viagra" preferredWord="Viagra" semType="phsu, orch"/><RxNorm RxCui="190465"/></Normalization></entity><entity charOffset="67:83" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.3" text="PDE-5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="other PDE-5 inhibitors." preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="1022271"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.3"/></relation><relation type="hasObject"><labelDrug text="Revatio"/><normalization><mmtx><preferredWord>Revatio</preferredWord><phraseText>&gt;REVATIO</phraseText><cuiCode>C1614029</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.3"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71" lineNumber="95" text="Concomitant use of REVATIO with nitrates in any form is contraindicated see Contraindications (4)." type="regular"><entity charOffset="19:26" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.0" text="REVATIO" type="Drug"><Normalization><mmtx cui="C1614029" phraseText="Concomitant use of REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="32:40" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.1" text="nitrates" type="Drug_Class"><Normalization><RxNorm RxCui="202927"/></Normalization></entity><entity charOffset="56:71" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.2" text="contraindicated" type="Caution_Interaction"/><entity charOffset="56:71" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.4" text="contraindicated" type="SPAN"/><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.0"/></relation><relation type="hasSeverity"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.0" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.1" severity="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.4" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.2" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73" lineNumber="97" text="Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended see Clinical Pharmacology (12.3)." type="regular"><entity charOffset="79:94" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.0" text="not recommended" type="Caution_Interaction"/><entity charOffset="19:26" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.2" text="REVATIO" type="Drug"><Normalization><mmtx cui="C1614029" phraseText="Concomitant use of REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><entity charOffset="32:41" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.3" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="with ritonavir" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="52:75" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.4" text="potent CYP3A inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.4" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.3" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.3" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.4"/></sentence><sentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76" text="In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. " type="negative"><entity charOffset="93:102" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.0" text="doxazosin" type="Biomedical_Entity"><Normalization><mmtx cui="C0114873" phraseText="the alpha-blocker doxazosin" preferredWord="Doxazosin" semType="phsu, orch"/><RxNorm RxCui="39173"/></Normalization></entity><entity charOffset="79:92" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.1" text="alpha-blocker" type="Biomedical_Entity"><Normalization><mmtx cui="C0001641" phraseText="the alpha-blocker doxazosin" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/><RxNorm RxCui="1023426"/></Normalization></entity><entity charOffset="217:226" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.2" text="doxazosin" type="Biomedical_Entity"><Normalization><mmtx cui="C0114873" phraseText="stabilized on doxazosin therapy." preferredWord="Doxazosin" semType="phsu, orch"/><RxNorm RxCui="39173"/></Normalization></entity><entity charOffset="34:44" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3" text="sildenafil" type="Biomedical_Entity"><Normalization><mmtx cui="C0529793" phraseText="sildenafil" preferredWord="sildenafil" semType="phsu, orch"/><RxNorm RxCui="136411"/></Normalization></entity><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.0"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.0"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.1" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.2"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.1"/><pair ddi="false" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.2"/></sentence><sentence biomedicalEntities="0" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.79" lineNumber="99" text="There were infrequent reports of patients who experienced symptomatic postural hypotension. " type="irregular"><entity charOffset="58:90" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.79.e.0" text="symptomatic postural hypotension" type="Specific_Interaction"/><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.79.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.79.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76" text="In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. "><entity charOffset="93:102" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.0" text="doxazosin" type="Drug"><Normalization><mmtx cui="C0114873" phraseText="the alpha-blocker doxazosin" preferredWord="Doxazosin" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.77" text="In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.78" text="Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. "/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76" text="In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. "><entity charOffset="34:44" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3" text="sildenafil" type="Drug"><Normalization><mmtx cui="C0529793" phraseText="sildenafil" preferredWord="sildenafil" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.77" text="In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.78" text="Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. "/></relation><relation type="hasContext"><ellipsisSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76" text="In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. "><entity charOffset="168:196" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.4" text="benign prostatic hyperplasia" type="SPAN"><Normalization><mmtx cui="C2937421" phraseText="with benign prostatic hyperplasia (BPH)" preferredWord="Prostatic Hyperplasia" semType="dsyn"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.77" text="In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.78" text="Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. "/></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="0" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.80" lineNumber="99" text="These reports included dizziness and light-headedness, but not syncope." type="irregular"><entity charOffset="23:32" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.80.e.0" text="dizziness" type="Specific_Interaction"><Normalization><mmtx cui="C0012833" phraseText="dizziness" preferredWord="Dizziness" semType="sosy"/><mmtx cui="C0042571" phraseText="dizziness" preferredWord="Vertigo" semType="sosy"/></Normalization></entity><entity charOffset="37:53" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.80.e.2" text="light-headedness" type="Specific_Interaction"><Normalization><mmtx cui="C0220870" phraseText="light-headedness," preferredWord="Lightheadedness" semType="sosy"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.80.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.80.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76" text="In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. "><entity charOffset="93:102" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.0" text="doxazosin" type="Drug"><Normalization><mmtx cui="C0114873" phraseText="the alpha-blocker doxazosin" preferredWord="Doxazosin" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.77" text="In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.78" text="Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.79" text="There were infrequent reports of patients who experienced symptomatic postural hypotension. "/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76" text="In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. "><entity charOffset="34:44" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3" text="sildenafil" type="Drug"><Normalization><mmtx cui="C0529793" phraseText="sildenafil" preferredWord="sildenafil" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.77" text="In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.78" text="Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.79" text="There were infrequent reports of patients who experienced symptomatic postural hypotension. "/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.80.ddi.2"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.80.e.2"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76" text="In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. "><entity charOffset="93:102" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.0" text="doxazosin" type="Drug"><Normalization><mmtx cui="C0114873" phraseText="the alpha-blocker doxazosin" preferredWord="Doxazosin" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.77" text="In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.78" text="Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.79" text="There were infrequent reports of patients who experienced symptomatic postural hypotension. "/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76" text="In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. "><entity charOffset="34:44" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3" text="sildenafil" type="Drug"><Normalization><mmtx cui="C0529793" phraseText="sildenafil" preferredWord="sildenafil" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.77" text="In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.78" text="Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. "/><middleSentence id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.79" text="There were infrequent reports of patients who experienced symptomatic postural hypotension. "/></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="2" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82" lineNumber="100" text="When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic." type="regular"><entity charOffset="115:165" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.0" text="mean additional reduction on supine blood pressure" type="Specific_Interaction"/><entity charOffset="5:15|23:27" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.2" text="sildenafil oral" type="Drug"><Normalization><mmtx cui="C0989893" phraseText="sildenafil 100 mg" preferredWord="sildenafil 100 MG" semType="clnd"/><RxNorm RxCui="136411"/></Normalization></entity><entity charOffset="53:63|79:83" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.3" text="amlodipine oral" type="Drug"><Normalization><mmtx cui="C0051696" phraseText="co-administered with amlodipine," preferredWord="Amlodipine" semType="phsu, orch"/><mmtx cui="C2346927" phraseText="5 mg" preferredWord="Magnesium Cation" semType="phsu, elii"/><mmtx cui="C2346927" phraseText="10 mg" preferredWord="Magnesium Cation" semType="phsu, elii"/><RxNorm RxCui="104416"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.2" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.3" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.82.e.0" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83" lineNumber="101" text="Monitor blood pressure when co-administering blood pressure lowering drugs with REVATIO see Warnings and Precautions (5.2)." type="regular"><entity charOffset="45:74" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.0" text="blood pressure lowering drugs" type="Drug_Class"><Normalization><mmtx cui="C0003364" phraseText="blood pressure lowering drugs with REVATIO" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="1629"/></Normalization></entity><entity charOffset="0:7" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.1" text="Monitor" type="Caution_Interaction"/><entity charOffset="80:87" id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.3" text="REVATIO" type="Drug"><Normalization><mmtx cui="C1614029" phraseText="blood pressure lowering drugs with REVATIO" preferredWord="Revatio" semType="phsu, orch"/><RxNorm RxCui="581642"/></Normalization></entity><drugInteraction id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.ddi.1"><interaction trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.1"><relations><relation type="hasObject"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.0" e2="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.3" trigger="Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.1" type="Caution_Interaction"/></sentence><positiveExamples number="17"/><negativeExamples number="26"/></document>